CAJ | 학술논문

淋巴瘤微小残留病(MRD)的准确检测对判断预后、评价疗效、监测复发和指导治疗具有十分重要的意义.免疫球蛋白(Ig)/T细胞受体(TCR)重排可以作为肿瘤特异性PCR标志用于MRD的监测.BIOMED-2策略是欧洲协作组制定的标准化多重PCR反应方法.MRD的检测可以通过实时荧光定量PCR的方法完成.对Ig/TCR重排监测儿童淋巴瘤MRD的原理及其相关研究进展进行了综述.
림파류미소잔류병(MRD)적준학검측대판단예후、평개료효、감측복발화지도치료구유십분중요적의의.면역구단백(Ig)/T세포수체(TCR)중배가이작위종류특이성PCR표지용우MRD적감측.BIOMED-2책략시구주협작조제정적표준화다중PCR반응방법.MRD적검측가이통과실시형광정량PCR적방법완성.대Ig/TCR중배감측인동림파류MRD적원리급기상관연구진전진행료종술.
Detection of minimal residual disease (MRD) exactly for lymphoma is important for estimating prognosis, assessing response, monitoring relapse and instructing treatment. Immunoglobulin (Ig)/T-cell receptor (TCR) gene rearrangements can be used as special tumorous markers for MRD testing by PCR.BIOMED-2 strategy is a method about multiplex PCR reaction designed by European Collaborative Organization. Monitoring MRD can be completed by real-time quantitative PCR. In this paper, the principle and research progress related to the application of IG/TCR in MRD detection are mainly reviewed for lymphoma in children.